Amgen — Aug 5, 2025 release

pts: percentage points * = Change in excess of 100% N/A = not applicable Cash Flow and Balance Sheet • The Company generated $1.9 billion of free cash flow in the second quarter of 2025 versus $2.2 billion in the second quarter of 2024, driven by timing of 2024 tax payments deferred to 2025 and higher capital expenditures, partially offset by business performance. • The Company declared a second quarter 2025 dividend on March 4, 2025 of $2.38 per share that was paid on June 6, 2025 to all stockholders of record as of May 16, 2025, representing a 6% increase from the same period in 2024. • The Company retired $1.4 billion of debt during the second quarter of 2025, and $4.3 billion year to date. • During the second quarter of 2025, there were no repurchases of shares of common stock. • Cash and cash equivalents totaled $8.0 billion and debt outstanding totaled $56.2 billion as of June 30, 2025. $Billions, except shares Q2 ’25 Q2 ’24 YOY Δ Operating Cash Flow $ 2.3  $ 2.5  $ (0.2) Capital Expenditures $ 0.4  $ 0.2  $ 0.1  Free Cash Flow $ 1.9  $ 2.2  $ (0.3) Dividends Paid $ 1.3  $ 1.2  $ 0.1  Share Repurchases $ 0.0  $ 0.0  $ 0.0  Average Diluted Shares (millions) 541  541  0  Note: Numbers may not add due to rounding AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 6/30/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 8.0  $ 12.0  $ (3.9) Debt Outstanding $ 56.2  $ 60.1  $ (3.9) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $35.0 billion to $36.0 billion. • On a GAAP basis, EPS in the range of $10.97 to $12.11, and a tax rate